Novo Nordisk’s Once-Weekly Sogroya Proves Effective in Children with Growth Disorders
Novo Nordisk presented data from the phase 3 REAL8 basket study, which showed that once-weekly Sogroya (somapacitan) was non-inferior to the once-daily growth hormone Norditropin…
Read More...
Read More...
